Claims:

1. 4-Trimethylammoniobutanoate acetylsalicylic acid addition salt, in particular that salt when characterized by an X-ray pattern having peaks at 20 values 5.10, 13.58,13.83,15.02,15.17,17.89,19.33,19.87, 21.85, 22.05, 23.32, 23.56, 23.92, 24.75, 25.55, 25.80, 27.05, 27.91, 30.25 ± 0.2°.

2. L-carnitine acetylsalicylic acid addition salt, in particular that salt when characterized by an X-ray pattern having peaks at 20 values 5.09,12.62, 13.48,13.84,15.04,17.82, 19.15,19.77, 21.84, 22.56, 23.33, 23.92, 24.40, 25.17, 25.43, 26.14, 27.24, 29.50, 30.36 + 0.2°.

3. 3-(Trimethylammonioamino)propanoate (meldonium) acetylsalicylic acid addition salt, in particular that salt when characterized by an X-ray pattern having peaks at 20 values 5.19,13.22,13.82,14.20,14.95, 15.36, 15.93,18.11,18.97,19.74, 21.02, 22.15, 23.15, 23.65, 24.31, 25.28, 26.18, 26.58, 27.73, 28.36 ± 0.2°.

4. 3-(Trimethylammonioamino)propanoate (meldonium) acetylsalicylic acid addition salt of claim 3, its solvates or polymorfs for use as medicament.

5. A pharmaceutical composition comprising 3-(trimethylammonioamino)propanoate (meldonium) acetylsalicylic acid addition salt of claim 3, and a pharmaceutically acceptable carrier.

6. The pharmaceutical composition of claim 5 adapted for oral administration.

7. A pharmaceutical composition of claim 5 for preventing and / or treating of inflammation, pain, fever, rheumatic conditions, hyperlipidemic condition, atherosclerotic condition, pathology induced by platelet aggregation or thrombi formation.

8. Composition of claim 7, wherein the pathology induced by platelet aggregation includes ischemic events such as myocardial infarction or stroke, or thrombosis and thromboembolism.

9. A combination medicinal product, comprising an effective amount of meldonium acetylsalicylic acid addition salt of claim 3 and one of

a) an effective amount of dipyridamole, the combination medicinal product being for use in preventing and/or treating a pathology induced by platelet aggregation, particularly stroke;

b) an effective amount of clopidogrel or pharmaceutically acceptable salt thereof, the combination medicinal product being for use in preventing and/or treating a pathology induced by platelet aggregation, particularly wherein the pathology induced by platelet aggregation includes ischemic events such as myocardial infarct or stroke, or thrombosis and thromboembolism, acute coronary syndrome, sudden cardiac death, and complications after coronary angioplasty or coronary artery bypasses; and

c) a statin, selected from the group of atorvastatin, cerivastatin, fluvastatin, lovastatin, mevastatin, pravastatin, pravastatin, rosuvastatin and simvastatin, preferably for use in preventing and/or treating of a disorder, selected from the group consisting of dyslipidemia, hyperlipidemia and atherosclerosis.

10. A combination medicinal product comprising an effective amount of meldonium acetyl salicylic acid addition salt of claim 3 and an effective amount of nicotinic acid or pharmaceutically acceptable salt thereof.

11. The product of claim 10, wherein one or both of

a) the meldonium acetylsalicylic acid addition salt, and
b) the nicotinic acid or pharmaceutically acceptable salt thereof

is in the form of immediate-release, sustained-release or extended-release formulation.

12. The combination medical product of claim 10 for use in preventing and/or treating of a pathology induced by platelet aggregation.

13. The product of claim 12, wherein the pathology induced by platelet aggregation includes ischemic events such as myocardial infarction or stroke, or thrombosis and thromboembolism.

14. The combination medical product of claim 10 for use in preventing and/or treating a disorder selected from the group consisting of dyslipidemia, hyperlipidemia and atherosclerosis.

Claims:

1. 3-(Trimethylammonioamino)propanoate (meldonium) acetylsalicylic acid addition salt, in particular that salt when characterized by an X-ray pattern having peaks at 2Θ values 5.19,13.22,13.82,14.20,14.95, 15.36, 15.93,18.11,18.97,19.74, 21.02, 22.15, 23.15, 23.65, 24.31, 25.28, 26.18, 26.58, 27.73, 28.36 ± 0.2°.

2. 3-(Trimethylammonioamino)propanoate (meldonium) acetylsalicylic acid addition salt of claim 1, its solvates or polymorfs for use as medicament.

3. A pharmaceutical composition comprising 3-(trimethylammonioamino)propanoate (meldonium) acetylsalicylic acid addition salt of claim 1, and a pharmaceutically acceptable carrier.

4. The pharmaceutical composition of claim 3 adapted for oral administration.

5. A pharmaceutical composition of claim 3 for preventing and / or treating of inflammation, pain, fever, rheumatic conditions, hyperlipidemic condition, atherosclerotic condition, pathology induced by platelet aggregation or thrombi formation.

6. Composition of claim 5, wherein the pathology induced by platelet aggregation includes ischemic events such as myocardial infarction or stroke, or thrombosis and thromboembolism.

7. A combination medicinal product, comprising an effective amount of meldonium acetylsalicylic acid addition salt of claim 1 and one of

a) an effective amount of dipyridamole, the combination medicinal product being for use in preventing and/or treating a pathology induced by platelet aggregation, particularly stroke;

b) an effective amount of clopidogrel or pharmaceutically acceptable salt thereof, the combination medicinal product being for use in preventing and/or treating a pathology induced by platelet aggregation, particularly wherein the

pathology induced by platelet aggregation includes ischemic events such as myocardial infarct or stroke, or thrombosis and thromboembolism, acute coronary syndrome, sudden cardiac death, and complications after coronary angioplasty or coronary artery bypasses; and

c) a statin, selected from the group of atorvastatin, cerivastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin and simvastatin, preferably for use in preventing and/or treating of a disorder, selected from the group consisting of dyslipidemia, hyperlipidemia and atherosclerosis.

8. A combination medicinal product comprising an effective amount of meldonium acetyl salicylic acid addition salt of claim 1 and an effective amount of nicotinic acid or pharmaceutically acceptable salt thereof.

9. The product of claim 8, wherein one or both of

a) the meldonium acetylsalicylic acid addition salt, and

b) the nicotinic acid or pharmaceutically acceptable salt thereof

is in the form of immediate-release, sustained-release or extended-release formulation.

10. The combination medical product of claim 8 for use in preventing and/or treating of a pathology induced by platelet aggregation.

11. The product of claim 10, wherein the pathology induced by platelet aggregation includes ischemic events such as myocardial infarction or stroke, or thrombosis and thromboembolism.

12. The combination medical product of claim 8 for use in preventing and/or treating disorder selected from the group consisting of dyslipidemia, hyperlipidemia and atherosclerosis.